Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas.
Details
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_A5E22C24DC29
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas.
Journal
Current radiopharmaceuticals
ISSN
1874-4729 (Electronic)
ISSN-L
1874-4710
Publication state
Published
Issued date
2020
Peer-reviewed
Oui
Volume
13
Number
2
Pages
94-98
Language
english
Notes
Publication types: Journal Article ; Systematic Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
Radiolabeled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors.
The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data.
A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas.
Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors.
Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.
The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data.
A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas.
Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors.
Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.
Keywords
Brain Neoplasms/diagnostic imaging, Glioblastoma/diagnostic imaging, Glioma/diagnostic imaging, Humans, Magnetic Resonance Imaging/methods, Male, Multimodal Imaging/methods, Positron Emission Tomography Computed Tomography/methods, Positron-Emission Tomography/methods, Prostate-Specific Antigen, Radiopharmaceuticals, Whole Body Imaging/methods, PET, PSMA, glioblastoma, glioma, positron emission tomography, prostate specific membrane antibodies
Pubmed
Web of science
Create date
31/05/2021 15:00
Last modification date
23/11/2022 7:14
Usage data
